| Literature DB >> 22321740 |
Jennifer S Tolman1, Miguel A Valvano.
Abstract
BACKGROUND: Burkholderia cenocepacia is an opportunistic pathogen causing life-threatening infections in patients with cystic fibrosis. The bacterium survives within macrophages by interfering with endocytic trafficking and delaying the maturation of the B. cenocepacia-containing phagosome. We hypothesize that B. cenocepacia undergoes changes in gene expression after internalization by macrophages, inducing genes involved in intracellular survival and host adaptation.Entities:
Mesh:
Year: 2012 PMID: 22321740 PMCID: PMC3296584 DOI: 10.1186/1471-2164-13-63
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Functional classification by COG designation of intracellular selectively captured sequences. Profiles of the functional classes of genes are shown as a percentage of all selectively captured sequences (scs). Also shown is the functional profile of the entire B. cenocepacia genome.
Figure 2Distribution of genes differentially expressed by intracellular . The outer pair of concentric circles represents both coding strands of the B. cenocepacia genome. The second pair of concentric circles represents genes with increased (outer) and decreased (inner) expression by intracellular B. cenocepacia. Percentage of G+C is also shown, with above average in yellow and below average in purple. Chromosome 3 is 3x scale; the plasmid is 17.5x scale.
Figure 3Functional classification by COG designation of genes differentially expressed by intracellular . Profiles of functional classes are shown as a percentage of all genes with significantly increased (green bar) or decreased (red bar) expression (-2 > log2 > 2, p < 0.05).
Figure 4Relative expression of genes with the greatest fold-change in intracellular . Heat map shows the 100 genes with the greatest ± fold-change (p < 0.05) in expression in intracellular bacteria relative to non-macrophage-exposed bacteria. Color scale from -60 to +60-fold change is indicated, with expression increased > 60-fold in blue, and decreased > 60-fold in purple. "BCA" has been omitted from gene names.
Figure 5Comparative macrophage entry and intracellular replication of parental and mutant . Entry (A) was calculated relative to initial inoculum, and replication (B) was calculated relative to entry; both were normalized relative to the parental control, set at 100% entry and 100% replication. Significance was determined using one-way ANOVA and Dunnett's Multiple Comparison Test. Mutants with a statistically significant difference from the parental strain (*p < 0.05, **p < 0.01, ***p < 0.001) could be complemented for both entry (C) and replication (D). Plasmid pDA12 is a vector control; pJTx is a complementation plasmid. Error bars indicate the standard error of the mean of at least three independent experiments. Vector control and complemented strains were compared using Student's t test; statistically significant differences are indicated above the lines.
Figure 6Comparative bacterial infection, host cytotoxicity, and normalized replication of parental and mutant . Bacterial infection and cytotoxicity (A) are shown as a percentage of total cells. Cytotoxicity was normalized against cell death in uninfected cells. 50 000 cells were counted in each of three independent experiments. Standard error bars are indicated. Significance was determined using one-way ANOVA and Dunnett's Multiple Comparison Test. Mutants demonstrating significant difference from the wild-type are indicated (*p < 0.05, **p < 0.01, ***p < 0.001). The ratio of dead cells: infected cells (B) was used to correct intracellular replication determined by the gentamicin protection assay to give the total expected ratio of intracellular bacteria in the absence of cell death (C). Mutants with a ratio in (B) less than zero are unchanged in (C).
Figure 7Spread of . Capacity to spread (A) is calculated as the fold-increase in infected macrophages when maintained in antibiotic-free media rather than 10 μg/ml gentamicin in the same experiment. Host cytotoxicity (B) is calculated as the ratio of total dead cells to infected cells. 50 000 cells were counted in each of three independent experiments. Standard error bars are indicated. Significance was determined using one-way ANOVA and Dunnett's Multiple Comparison Test. Mutants demonstrating significant difference from the wild-type are indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
Strains, plasmids, and cell lines used in this study
| Strain, cell line, or plasmid | Relevant characteristicsa | Source or reference |
|---|---|---|
| DH5α | F-, ɸ 80 | Laboratory stock |
| SY327 | [ | |
| J2315 | Epidemic strain ET12 clone, CF clinical isolate | P.A. Sokol |
| K56-2 | Epidemic strain ET12 clone, CF clinical isolate | BCRRCb |
| MH1K | K56-2 ΔBCAL1674-6 | [ |
| JST19 | MH1K ΔBCAL0124 | This study |
| JST71 | MH1K ΔBCAS0186 | This study |
| JST75 | MH1K ΔBCAM2837 | This study |
| JST128 | MH1K ΔBCAL1726 | This study |
| JST130 | MH1K ΔBCAM0276 | This study |
| JST132 | MH1K ΔBCAM0411 | This study |
| JST134 | MH1K ΔBCAM2446 | This study |
| JST136 | MH1K ΔBCAM0434-5 | This study |
| JST190 | MH1K ΔBCAL0340 | This study |
| JST194 | MH1K ΔBCAM1679 | This study |
| Macrophage cell lines | ||
| ANA-1 | C57BL/6 murine bone marrow-derived macrophages | [ |
| RAW 264.7 | BALB/c murine macrophage cell line | ATCCc |
| Plasmid | ||
| pDA12 | [ | |
| pDA42 | pDA12, | [ |
| pDAI-SceI-SacBN | [ | |
| pDelbcsM | pGPI-SceI with regions flanking BCAL0340 | [ |
| pGPI-SceI | [ | |
| pJT25 | pUC19 with K56-2 rDNA (23S, 16S, 5S), ApR | This study |
| pJT31 | pGPI-SceI with regions flanking BCAL0124 | This study |
| pJT41 | pGPI-SceI with regions flanking BCAS0186 | This study |
| pJT42 | pGPI-SceI with regions flanking BCAM2837 | This study |
| pJT45 | pGPI-SceI with regions flanking BCAL1726 | This study |
| pJT46 | pGPI-SceI with regions flanking BCAM0276 | This study |
| pJT47 | pGPI-SceI with regions flanking BCAM0411 | This study |
| pJT48 | pGPI-SceI with regions flanking BCAM2446 | This study |
| pJT49 | pGPI-SceI with regions flanking BCAM0434-5 | This study |
| pJT52 | pDA12, BCAL1726 | This study |
| pJT54 | pDA12, BCAM0411 | This study |
| pJT57 | pDA12, BCAL0124 | This study |
| pJT71 | pDA12, BCAL0340 | This study |
| pJT72 | pGPI-SceI with regions flanking BCAM1679 | This study |
| pRK201 | RK2 derivative, KmR, | [ |
| pUC19 | [ |
a Tp, trimethoprim; Tet, tetracycline; Ap, ampicillin; Km, kanamycin
b B. cepacia complex Research and Referral Repository for Canadian CF Clinics
c American Type Culture Collection